ICB or ICB plus TKIs targeting programmed cell death 1 (PD-1), programmed cell death ligand 1 (PD-L1), and cytotoxic T-lymphocyte-associated antigen 4 (CTLA4) are now the standard of care for RCC [11, 12]. Here, CTLA4 is linked to renal cell carcinoma.